[go: up one dir, main page]

MX2009009332A - Antagonista del receptor de mineralocorticoides para el tratamiento de endometriosis. - Google Patents

Antagonista del receptor de mineralocorticoides para el tratamiento de endometriosis.

Info

Publication number
MX2009009332A
MX2009009332A MX2009009332A MX2009009332A MX2009009332A MX 2009009332 A MX2009009332 A MX 2009009332A MX 2009009332 A MX2009009332 A MX 2009009332A MX 2009009332 A MX2009009332 A MX 2009009332A MX 2009009332 A MX2009009332 A MX 2009009332A
Authority
MX
Mexico
Prior art keywords
endometriosis
treatment
mineralcorticoid receptor
receptor antagonists
present
Prior art date
Application number
MX2009009332A
Other languages
English (en)
Inventor
Ulrike Fuhrmann
Carsten Moeller
Anja Schmidt
Ulrike Kaufmann-Reiche
Oliver-Martin Fischer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MX2009009332A publication Critical patent/MX2009009332A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Es objeto de la presente invención el uso de antagonistas del receptor de mineralocorticoides para preparar un medicamento para el tratamiento de endometriosis. En especial, la presente invención se refiere a un agente terapéutico mejorado contra la endometriosis, que muestra un perfil de acción o de efectos colaterales más ventajoso que las terapias de tratamiento disponibles hasta ahora. Con un antagonista del receptor de mineralocorticoides se puede tratar la endometriosis de modo duradero, sin que se produzca, en este caso, una pérdida de la masa ósea.
MX2009009332A 2007-03-02 2008-02-28 Antagonista del receptor de mineralocorticoides para el tratamiento de endometriosis. MX2009009332A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007011105A DE102007011105A1 (de) 2007-03-02 2007-03-02 Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
PCT/EP2008/052456 WO2008107373A1 (de) 2007-03-02 2008-02-28 Mineralcorticoid-rezeptor-antagonisten zur behandlung von endometriose

Publications (1)

Publication Number Publication Date
MX2009009332A true MX2009009332A (es) 2009-09-11

Family

ID=39431148

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009332A MX2009009332A (es) 2007-03-02 2008-02-28 Antagonista del receptor de mineralocorticoides para el tratamiento de endometriosis.

Country Status (15)

Country Link
US (1) US20110003778A1 (es)
EP (1) EP2131825A1 (es)
JP (1) JP2010520178A (es)
KR (1) KR20090119870A (es)
CN (1) CN101621995A (es)
AR (1) AR065585A1 (es)
AU (1) AU2008223859A1 (es)
BR (1) BRPI0808427A2 (es)
CA (1) CA2679520A1 (es)
DE (1) DE102007011105A1 (es)
IL (1) IL200380A0 (es)
MX (1) MX2009009332A (es)
RU (1) RU2009136305A (es)
TW (1) TW200900080A (es)
WO (1) WO2008107373A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1003661A2 (pt) * 2010-09-15 2013-01-08 Libbs Farmaceutica Ltda associaÇço farmacÊutica para tratar e/ou prevenir mioma e/ou endometriose, uso de resveratrol e progestogenio, composiÇço farmacÊutica para tratamento e/ou prevenÇço de mioma e/ou endometriose medicamento para tratamento e/ou prevenÇço de mioma e/ou endometrios, kit e mÉtodo para tratamento e/ou prevenÇço de mioma e/ou endometriose
EA201400537A1 (ru) 2011-11-04 2014-10-30 Байер Фарма Акциенгезельшафт 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
WO2014115449A1 (ja) * 2013-01-22 2014-07-31 シャープ株式会社 液晶表示装置
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
CN117959293B (zh) * 2024-01-18 2025-05-13 香港大学深圳医院 非奈利酮在制备治疗和/或预防卵巢功能障碍疾病药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4042004A1 (de) * 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
DE4042005A1 (de) * 1990-12-22 1992-06-25 Schering Ag D-homo-(16-en)-11(beta)-aryl-4-estrene
SK287192B6 (sk) 1999-08-31 2010-02-08 Bayer Schering Pharma Aktiengesellschaft Mezoprogestíny (modulátory receptora pre progesterón) na liečenie a prevenciu benígnych gynekologických ochorení závislých od hormónov
RS52149B (sr) * 2000-01-18 2012-08-31 Bayer Schering Pharma Aktiengesellschaft Farmaceutska kombinacija mikronizovanog drospirenona i estrogena za terapiju zamene hormona
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
FR2886151B1 (fr) * 2005-05-31 2007-09-07 Mayoly Spindler Soc Par Action Utilisation de la colchicine pour la preparation d'un medicament destine a la prevention et/ou au traitement de l'endometriose

Also Published As

Publication number Publication date
CN101621995A (zh) 2010-01-06
DE102007011105A1 (de) 2008-09-04
AR065585A1 (es) 2009-06-17
EP2131825A1 (de) 2009-12-16
AU2008223859A1 (en) 2008-09-12
IL200380A0 (en) 2010-04-29
TW200900080A (en) 2009-01-01
JP2010520178A (ja) 2010-06-10
KR20090119870A (ko) 2009-11-20
US20110003778A1 (en) 2011-01-06
RU2009136305A (ru) 2011-04-10
CA2679520A1 (en) 2008-09-12
BRPI0808427A2 (pt) 2014-07-22
WO2008107373A1 (de) 2008-09-12

Similar Documents

Publication Publication Date Title
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
IN2012DN02177A (es)
IN2012DN02730A (es)
IN2012DN00754A (es)
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MX2011012691A (es) Combinacion de un antagonista de tnf-alfa y un antagonista de vegf para utilizarse en el tratamiento o en la prevencion de enfermedades de los ojos.
MX2009009332A (es) Antagonista del receptor de mineralocorticoides para el tratamiento de endometriosis.
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
MX2015002292A (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r.
MY158257A (en) Forms of rifaximin and uses thereof
AU2011328009A8 (en) Compounds and methods for treating pain
IN2012DN02782A (es)
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
EP2328414A4 (en) SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
EA200870425A1 (ru) Применение агонистов рецептора grp119 для повышения костной массы и для лечения остеопороза и связанной с ними комбинированной терапии
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
PH12013501244A1 (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
EP2019646A4 (en) METHOD, DEVICE AND SYSTEM FOR THE RELEASE OF A THERAPEUTIC ACTIVE IN THE EYE
IN2012DN02471A (es)
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights
HC Change of company name or juridical status